METTL3 and acute myeloid leukemia: optimized a METTL3 hit compound using medicinal chemistry and protein crystallography techniques, ultimately leading to the development of lead compound UZH2, and it specifically inhibits intracellular METTL3 activity and significantly decreases the m6A levels in AML and PCa cell lines (95).